TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Physiological Effects of Deferred Cord Clamping

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Greater than ≥ 32 weeks gestation~* With written informed parental consent~Exclusion Criteria:~* Antenatally diagnosed problems requiring immediate intervention or problems at delivery are anticipated.~* No realistic prospect of survival~* No parental consent~* Maternal death~* Non-singleton pregnancies

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Hours
- Healthy Volunteers: f

Study Arms:
- Deferred Clamping (Type: None): Infants undergoing a deferring of umbilical cord clamping for 30 seconds or more
- Immeadiate Cord Clamping (Type: None): Infants undergoing immediate umbilical cord clamping in the first 20 seconds of life.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes treated with CSII at least 3 months.~* Males and females, \> 18 years but \< 75 years old.~* Hemoglobin A1c ≤ 8.0 % at measurement taken at week 0 (screening visit).~* Duration of diabetes ≥ 12 months.~* Willingness to perform self-blood glucose monitoring several times/day.~Exclusion Criteria:~* Previous insulin precipitation in pump infusion catheters.~* Daily insulin requirements \> 25% of pump reservoir capacity. (This would preclude the subject from using the pump infusion system for more than 3 days).~* Use of an insulin pump that does not have a downloadable record of basal and bolus doses.~* Known or suspected allergy to trial products.~* Pregnancy, breast-feeding, intention to become pregnant or inadequate contraception measures.~* Known or suspected alcohol or drug abuse.~* Impaired renal function with creatinine ≥ 1.7 mg/dl.~* Pronounced catheter site scarring.~* Chronic use of drugs that may influence glycemic control (e.g. steroids).~* Any other significant concomitant disease that would interfere with participation in and completion of the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Insulin Aspart Versus Insulin Lispro (Type: ACTIVE_COMPARATOR): Insulin aspart will be used for diabetes management, and will be delivered continuously, subcutaneously using a pump for a four week period. Insulin aspart doses will be adjusted by the principal investigator as needed to maintain glycemic control. Insulin dose adjustments will vary from patient to patient based on the carbohydrate consumption, level of physical activity, and fingerstick monitoring results SMBG (7 times per day). SMBG results collected during this four week period will be compared to the SMBG results collected while participant uses alternative treatment (insulin Lispro).
- Insulin Lispro Versus Insulin Aspart (Type: ACTIVE_COMPARATOR): Insulin lispro will be used for diabetes management, and will be delivered continuously, subcutaneously using a pump for a four week period. Dose will be adjusted as needed to maintain glycemic control. Insulin dose adjustments will vary from patient to patient based on the carbohydrate consumption, level of physical activity, and fingerstick monitoring results SMBG (7 times per day). SMBG results collected during this four week period will be compared to the SMBG results collected while participant uses alternative treatment (insulin Aspart).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of KP-1461 to Treat ART-Experienced HIV+ Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Asymptomatic HIV-1-infected individuals who are treatment-experienced and who have not been on ART for at least 16 weeks.~* Have documented prior non-suppressive ART including at least 1 NRTI, 1 NNRTI and 2 PIs; or have documented prior ART resistance to at least 1 NRTI, 1 NNRTI and 1 PI; AND in the opinion of the investigator, have few, if any, effective treatment options available.~* Have \>2,500 copies/mL of HIV-1 RNA at screening.~* Have a stable CD4 cell count while off ART and \>250 cells/mL at screening.~* Have no clinically significant findings on screening evaluations.~Exclusion Criteria:~* Have a current or recent opportunistic infection that, in the opinion of the investigator, is not being controlled by medication.~* Have any condition that, in the opinion of the investigator, could compromise subject safety or adherence to the protocol.~* Have a documented positive test for hepatitis B surface antigen, or have received any antiviral therapy for hepatitis C \<6 weeks prior to study drug administration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven relapsed or refractory, low grade or transformed low grade B-cell non-Hodgkin's lymphoma including the following: Small lymphocytic Follicular small cleaved cell Follicular mixed small cleaved and large cell (less than 50% large cell component) Tumor must be positive for CD20 antigen Relapse or disease progression following at least 1 chemotherapy regimen or failure to achieve an objective response (complete or partial response) on prior chemotherapy regimen No disease progression, within 1 year of irradiation, arising in a field previously irradiated with more than 3500 cGy Mean of no greater than 25% intratrabecular marrow space involved with lymphoma on bilateral iliac crest bone marrow biopsy A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of indolent or aggressive lymphoma will replace the former terminology of low, intermediate, or high grade lymphoma. However, this protocol uses the former terminology.~PATIENT CHARACTERISTICS: Age: 19 and over Performance status: Karnofsky 60-100% Life expectancy: At least 3 months Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 1.5 times upper limit of normal (ULN) AST less than 5 times ULN Renal: Creatinine less than 1.5 times ULN No active obstructive hydronephrosis Cardiovascular: No New York Heart Association class III or IV heart disease Other: No active infection requiring IV antibiotics No other concurrent illness that would preclude evaluation No prior malignancy within the past 5 years except adequately treated skin cancer, carcinoma in situ of the cervix, or lymphoma HIV negative Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 6 months after study No prior allergic reaction to iodine other than IV iodine containing contrast materials Human antimouse antibody negative~PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy or cytokine treatment and recovered No prior hematologic stem cell transplantation Chemotherapy: See Disease Characteristics At least 4 weeks since prior chemotherapy (at least 6 weeks since prior nitrosoureas) and recovered Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiotherapy and recovered No prior radioimmunotherapy Surgery: Not specified Other: No concurrent IV antibiotics

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative and Intraoperative Quantification of Axillary Tumoral Load

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Breast cancer patients with infiltrated axillary lymph nodes cT1-4 cN1~* Older than 18 years old~* Able to understand and accept the protocol procedure and to sign an informed consent form in accordance with national legislation.~Exclusion Criteria:~* Breast cancer patients in whom no information about axillary lymph nodes status (cytology or biopsy) is available.~* Patients younger than 18 years old.~* Psychiatric disease~* Difficulties to understand Spanish.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Breast cancer patients with infiltrated axillary l (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Radiofrequency Ablation of Uterine Fibroids

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Diagnosed with uterine leiomyomas (fibroids)~* Patient will undergo surgical hysterectomy~* Patient is willing to sign informed consent form~Exclusion Criteria:~* Patients with acute infection~* Patients with bleeding disorders~* Patients who are not candidates for surgery or general anesthesia

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Written informed consent obtained prior to any screening procedures~2. Age greater than or equal to 18 years old~3. Participants with biopsy-confirmed stages IB-IVA mycosis fungoides or Sézary syndrome (SS). Participants with SS who have bone marrow involvement are also eligible. Participants with transformed CTCL are eligible~4. Participants must have been treated with an HDAC inhibitor given for the treatment of CTCL. Participants must have had disease progression on or following treatment with an HDAC inhibitor. Participants are also eligible if they had an inadequate response to an HDAC inhibitor defined as stable disease as the best response after at least 3 months of therapy. Participants previously treated with an HDAC inhibitor are also eligible if they experienced intolerance due to adverse events.~5. Baseline multiple-gated acquisition scan (MUGA) or echocardiogram must have demonstrated left ventricular ejection fraction (LVEF) ≥ the lower limit of the institutional normal~6. ECOG performance status ≤ 2~Exclusion criteria:~1. Participants with a history of visceral disease including central nervous system (CNS) involvement (i.e. stage IVB CTCL). Note, participants who have SS with bone marrow involvement are eligible~2. Impaired cardiac function~3. Concomitant use of drugs with a risk of causing torsades de pointes~4. Participants who have received chemotherapy or any investigational drug or undergone major surgery ≤ 3 weeks prior to starting study drug or who have not recovered from side effects of such therapy~5. Less than 3 months since prior electron beam therapy~6. Women who are pregnant or breast feeding, or women of childbearing potential (WOCBP) not willing to use a double method of contraception during the study and 3 months after the end of treatment.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Panobinostat 20 mg (Type: EXPERIMENTAL): Participants received panobinostat, 20 milligrams (mg), capsules, orally, thrice weekly on alternate Days 1, 3, and 5 per week of a 28-day treatment cycle until unacceptable toxicity, disease progression, and/or physician's discretion to discontinue the treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transversal, Controlled and Not Randomized Study, Laying on the Desire of Children and Eating Disorders in a Population of Infertile Women

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women~* Major~* In a relationship~* Infertile (WHO criteria)~* Consultant in the Department of infertility (BMDR) for AMP~* Understanding of French, literate~* Agree to participate in the study~Exclusion Criteria:~* Man~* Minor~* Pregnancy at the time of assessment~* Exclusive Infertility spouse~* Disorders of higher functions (severe cognitive impairment or confusion) or psychosis (hallucinations, delusional syndrome)~* Major protected

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Without eating disorders (Type: OTHER): Women consulting for infertility but without diagnosis of eating disorder.
- With Eating disorders (Type: OTHER): Womenconsulting for infertility for which eating disorder is diagnosed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Imatinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (Age ≧ 20) who received the first allo-HSCT are eligible;~* Patients with underlying disease of acute leukemia in morphological remission, or myelodysplastic syndrome;~* Received allo-HSCT with HLA-matched sibling or unrelated donors (at least 8/8 match for HLA-A/B/C/DR);~* Evidence of post-transplantation neutrophil engraftment: absolute neutrophil count \> 500/mm3 for at least 3 consecutive days;~* No detectable CMV infection before study enrollment: negative plasma CMV DNA surveillance within passing 2 weeks;~* No previous post-transplantation anti-CMV therapy and no planned prophylactic anti-CMV therapy;~* The patients has the ability to swallow tablets~Exclusion Criteria:~* They have renal insufficiency: serum creatinine \> 2.5 mg/dL;~* They have hepatic dysfunction: serum alanine or aspartate aminotransferase levels of \> 5 times the upper limit of the normal range or a serum total bilirubin of \> 3 mg/dL;~* Patients with history of HIV infection;~* Unstable post-BMT condition or other medical condition deemed not appropriate to be included to this study as judged by investigator;~* Life expectancy less than 3 months;~* Unwillingness or unable to give consent;~* Patients with diseases that are positive for t(9;22) or BCR-ABL fusion gene.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imatinib (Type: EXPERIMENTAL): Imatinib (100 mg/tablet) 2# per day till D+100 after allo-HSCT or prophylaxis failure.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 2# per day till D+100 after allo-HSCT or prophylaxis failure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients age 18 and older who underwent an allogeneic hematopoietic stem cell transplantation.~* Patients are required to have biopsy proven GVHD.~* Patients must have active acute GVHD requiring systemic immune suppressive therapy and that failed or did not respond to first line of therapy.~  * First line therapy needs to be a minimum of corticosteroids, methylprednisolone of 1.6mg/kg/day or prednisone of 2mg/kg/day, alone or combined to other agent.~ * Failure of GVHD therapy is defined as flare of signs and symptoms of acute GVHD or progression of GVHD grade after at least 72 hours from starting therapy.~ * No response to GVHD treatment (corticosteroids ± other agent) after a minimum of 7 days of treatment.~* Patient must be able to give informed consent.~Exclusion Criteria:~* Intolerance or allergy to Tocilizumab~* Active uncontrolled infection requiring ongoing treatment with antifungals, antibiotics or anti-viral drugs.~* Relapsed/persistent malignancy requiring rapid immune suppression withdrawal.~* Liver enzymes: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \> 3x upper limit of normal.~* Patients with severe sinusoidal obstruction syndrome who in the judgment of the treating physician are not expected to have normalized bilirubin by day 56 after enrollment.~* Serum bilirubin \> 2x upper limit of normal.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab (Type: EXPERIMENTAL): Drug: Tocilizumab~Other Names:~Actemra~Tocilizumab will be administered intravenously at a dose of 8 mg/kg once every three weeks for three doses. After Day 56 doses may be decreased to 4mg/kg once every three weeks depending on GVHD response.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults age 19 and over~2. Clinical diagnosis of genital warts requiring treatment based on clinician evaluation~3. Fluency in English~4. Available within four days of the intended 8 week follow-up visit~Exclusion Criteria:~1. Individuals under the age of 19~2. Pregnant women~3. Known contraindication to zinc Signs of copper/iron deficiency which include anemia and neutropenia which are characterized by tiredness, fatigue and light headedness.~4. Diseases that alter zinc metabolism or absorption eg. type II diabetes mellitus, Crohn's disease, chronic leg ulcers~5. Clients who are currently taking zinc for therapeutic purposes or have taken zinc in the last two months for therapeutic purposes~6. Clients who have received standard of care treatment for their warts in the past month

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oral Zinc (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Enteral Glutamine in Critical Illness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admission to MICU/ CICU~* Age greater than or equal to 18 years old~* Requirement for enteral nutrition~* Presence or planned insertion of central venous catheter as part of routine medical care~* Requirement for mechanical ventilation~* APACHE II Score \>/= 15~Exclusion Criteria:~* Female of child-bearing age (i.e. less than 45 years old)~* Enteral nutrition begun prior to randomization~* Receiving Total Parenteral Nutrition~* Requirement for protein restriction~* Creatinine \>4 mg/dl~* History of cirrhosis and/or clinical signs of heptic encephalopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Will receive enteral glutamine
- B (Type: NO_INTERVENTION): No enteral glutamine given

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues